Biochemics signs research collaboration agreement with Unilever

BioChemics, Inc. a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Unilever, one of the world’s largest consumer goods companies, to utilize BioChemics’ proprietary topical delivery technology for the delivery of Unilever’s compounds.

"We are delighted to be working with Unilever to evaluate the broader applications of our technology for their products," said President and Chief Executive Officer John J. Masiz, Esq.

“In addition to our other ongoing collaborations, this agreement further validates the impact for our proprietary topical technology, making us attractive to a wide variety of partners to develop well-differentiated, cost-effective products for consumers.”